Governance Poolbeg Pharma PLC

POLB

GB00BKPG7Z60

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 10:05:08 14/01/2026 pm IST			5-day change	1st Jan Change
4.990 ^GBX	+2.89%		+16.05%	+24.75%

26/12	Certain Ordinary Shares of Poolbeg Pharma PLC are subject to a Lock-Up Agreement Ending on 26-DEC-2025.	CI
08/12	Poolbeg Pharma plc Announces the POLB 001 Trial Is to Feature in Cancer Immunotherapy-Induced CRSResearch Programme	CI

Executive Committee: Poolbeg Pharma PLC

Manager

Positions heldSince

Jeremy Skillington

55 year

Chief Executive Officer

01/05/2021

Ian O'Connell

39 year

Director of Finance/CFO

01/01/2021

Bruno Speder

General Counsel

01/07/2022

Ross Crockett

Comptroller/Controller/Auditor

01/06/2021

Carol Dalton

Investor Relations Contact

01/01/2021

John McEvoy

39 year

General Counsel

01/01/2024

Laura Maher

Chief Tech/Sci/R&D Officer

08/01/2024

Composition of the Board of Directors: Poolbeg Pharma PLC

Director

CommitteesSince

Cathal Friel

61 year

Audit Committee

01/09/2020

Eddie Gibson

52 year

Audit Committee Chair	30/11/2023
Compensation Committee Chair	01/07/2021

Brendan Buckley

75 year

Compensation Committee Chair

30/11/2023

Luke O'Neill

62 year

Director/Board Member
Independent Dir/Board Member

Jeremy Skillington

55 year

Director/Board Member

01/05/2021

Ian O'Connell

39 year

Director/Board Member

20/05/2021

Latest Appointments: Poolbeg Pharma PLC

23/25/23	Poolbeg upsizes offer; Glenveagh backs outlook	AN
15/24/15	Diversified Energy offers dividend alternative	AN
15/24/15	Poolbeg Pharma's Nonexecutive Chair Transitions to Executive Role	MT
15/24/15	Poolbeg Pharma plc Appoints Cathal Friel as Executive Chairman	CI
13/24/13	Katoro Gold launches fundraising, eyes board shake-up	AN
30/23/30	Poolbeg Pharma plc Announces Directorate Changes	CI
09/23/09	Poolbeg Pharma appoints former Amryt executives to team	AN

More news

Former Officers and Directors: Poolbeg Pharma PLC

Insider

Positions held

SinceUntil

Patrick Ashe

Director/Board Member	-	30/11/2023
Independent Dir/Board Member	-	30/11/2023

David English

Corporate Officer/Principal

01/09/2022

01/10/2023

Salim Hamir

Corporate Secretary

11/05/2023

Age distribution of managers

Parity Men Women

Male	10
Female	2

Of which Executive Committee

Male	5
Female	2

Of which Directors

Male	6
Female	0

Poolbeg Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is engaged in the development of medicines to address the unmet need for infectious and other prevalent diseases. The Company is involved in the development of a range of pharmaceutical products. Its product pipeline includes POLB 001, POLB 001 Oncology, POLB 001 Influenza, AI Programs, Oral GLP-1R Agonist. Its POLB 001 aims to target the Cytokine Release Syndrome (CRS) associated with many cancer immunotherapy treatments which impacts 70% of patients undergoing CAR T or Bispecific Antibody therapy. The Company uses artificial intelligence to identify infectious disease drug targets & treatments. Its Oral GLP-1R Agonist is a delivery system which offers a scalable, natural, Generally Regarded As Safe (GRAS) approved solution for the oral delivery of metabolic peptide cargo to specific areas of the gut and into systemic circulation for the treatment of diabetes, obesity and other metabolic diseases.

Employees

Sector

Biotechnology & Medical Research

Calendar

26/02 - Q4 2025 Earnings Release (Projected)

More about the company